Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
- Conditions
- Invasive Fungal Infections
- Registration Number
- NCT06433128
- Lead Sponsor
- Basilea Pharmaceutica
- Brief Summary
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of fosmanogepix against resistant fungal pathogens in invasive fungal infections?
How does fosmanogepix compare to standard-of-care antifungal agents in treating life-threatening invasive fungal infections?
Which biomarkers are used to identify patients suitable for fosmanogepix treatment in expanded access programs?
What adverse events are associated with fosmanogepix in patients with refractory invasive fungal infections?
Are there any combination therapies or competitor drugs for invasive fungal infections similar to fosmanogepix?